Linked Life Data

15897578

Source:http://linkedlifedata.com/resource/pubmed/id/15897578

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2005-5-17
pubmed:abstractText
Heme oxygenase-1 (HO-1) is believed to represent a key enzyme for the protection of cells against "stress." Its overexpression in different types of human cancers supports the notion that HO-1 provides a growth advantage and contributes to cellular resistance against chemotherapy and radiotherapy. Given the poor survival rates of patients with pancreatic cancer due to its aggressive growth behavior and its exceptional resistance to all known forms of anticancer treatment, we have investigated the expression of HO-1 in human pancreatic cancer cells growth behavior and prognosis. Expression of HO-1 was analyzed in human pancreatic cancer samples in comparison with normal pancreas by quantitative PCR, Western blot, and confocal microscopy. The influence of radiotherapy and chemotherapy on HO-1 expression in pancreatic cancer cell lines was evaluated. Furthermore, HO-1 expression was specifically suppressed by small interfering RNA transfection and subsequently the alterations of growth behavior and resistance to anticancer treatment were tested. Human pancreatic cancer showed a 6-fold and 3.5-fold HO-1 up-regulation in comparison to normal pancreas based on mRNA and protein level, respectively (P < 0.05). Cancer tissues revealed marked HO-1 immunoreactivity in tumor cells and in tumor associated immunocytes. Treatment of the pancreatic cancer cell lines with gemcitabine or radiation strongly induced HO-1 expression. Targeted knockdown of HO-1 expression led to pronounced growth inhibition of the pancreatic cancer cells and made tumor cells significantly more sensitive to radiotherapy and chemotherapy. Therefore, specific inhibition of HO-1 expression may be a new option in pancreatic cancer therapy and may be used as sensitizer to chemotherapy and radiotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3790-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15897578-Adult, pubmed-meshheading:15897578-Aged, pubmed-meshheading:15897578-Antineoplastic Agents, pubmed-meshheading:15897578-Blotting, Western, pubmed-meshheading:15897578-Carcinoma, Pancreatic Ductal, pubmed-meshheading:15897578-Cell Proliferation, pubmed-meshheading:15897578-Drug Resistance, Neoplasm, pubmed-meshheading:15897578-Female, pubmed-meshheading:15897578-Heme Oxygenase (Decyclizing), pubmed-meshheading:15897578-Heme Oxygenase-1, pubmed-meshheading:15897578-Humans, pubmed-meshheading:15897578-Male, pubmed-meshheading:15897578-Membrane Proteins, pubmed-meshheading:15897578-Microscopy, Confocal, pubmed-meshheading:15897578-Middle Aged, pubmed-meshheading:15897578-Pancreatic Neoplasms, pubmed-meshheading:15897578-Polymerase Chain Reaction, pubmed-meshheading:15897578-RNA, Messenger, pubmed-meshheading:15897578-Radiation Tolerance, pubmed-meshheading:15897578-Tumor Cells, Cultured, pubmed-meshheading:15897578-Up-Regulation
pubmed:year
2005
pubmed:articleTitle
Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment.
pubmed:affiliation
Division of Pancreatic Surgery and Molecular Pancreatic Research, Department of General Surgery, Institute of Immunology, University of Heidelberg, Heidelberg, Germany.
pubmed:publicationType
Journal Article, Comparative Study